-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $7

Benzinga·11/06/2026 19:24:38
Listen to the news
Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $9 to $7.